PEP-CMV is under clinical development by Immunomic Therapeutics and currently in Phase I for Anaplastic Astrocytoma.

Toll-like receptors (TLRs) are crucial to trigger anticancer immune responses. Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible combination with Hookipa, an Austrian biotech that ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...

Former triathlon champ Claudia McCoy used the breakthrough wearable ultrasound unit to boost her recovery from injuries so ...

Inflammation is a crucial part of the body's defense mechanism, playing a key role in fighting infections and repairing tissue damage. Basophils, a ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever ...

A recent study by researchers at Institute of Science Tokyo reveals the pivotal role of tristetraprolin (TTP), an RNA-binding ...

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release ...